Search clinical trials for: Olodaterol/Tiotropium Bromide

Total 937 results

Boehringer Ingelheim

Completed

A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

Asthma

Austria, Germany, Poland, Romania, Slovakia, Slovenia
Boehringer Ingelheim

Completed

Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Tiotropium / Respimat One-Year Study

Pulmonary Disease, Chronic Obstructive

Austria, Canada, Spain, United States, Finland, Italy, Russian Federation, United Kingdom, New Zealand, Australia, France, Greece, Ireland, Netherlands, South Africa
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease (LaCrossE)

Chronic Obstructive Pulmonary Disease

Sweden
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

Pulmonary Disease, Chronic Obstructive

Australia, Austria, Canada, France, Germany
Boehringer Ingelheim

Completed

Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma

Pulmonary Disease, Chronic Obstructive | Asthma

Netherlands, Germany, Belgium, France, Canada, Italy, South Africa, Denmark
GlaxoSmithKline

Completed

Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

Asthma

United States, Australia, Canada, Denmark, Germany, Italy, Japan, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Turkey, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Terminated

Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD

Pulmonary Disease, Chronic Obstructive

United States, Canada
University of Dundee
Tenovus Scotland

Completed

Ultra-long Acting Bronchodilator Therapy in Asthmatics (MAN02)

Asthma

United Kingdom
GlaxoSmithKline

Completed

Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany
Novartis Pharmaceuticals

Completed

Effect of Indacaterol on Inspiratory Capacity (IC)

Chronic Obstructive Pulmonary Disease

Germany
ThomasTruncale
Boehringer Ingelheim

Completed

The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease | Chronic Bronchitis

United States
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)

Asthma

United States, Australia, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Serbia, South Africa, Turkey, Ukraine, United Kingdom
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma

Asthma

Japan
Boehringer Ingelheim

Completed

Tiotropium / Respimat One-Year Study

Pulmonary Disease, Chronic Obstructive

Germany, Canada, Spain, Russian Federation, United States, Belgium, France, Greece, Sweden, Norway, Turkey, Australia, Netherlands, United Kingdom
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Belgium, Netherlands
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Terminated

Bronchodilators and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Italy
Federal University of São Paulo

Completed

Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients

Pulmonary Disease, Chronic Obstructive | Pulmonary Emphysema | Chronic Bronchitis

Brazil
Boehringer Ingelheim

Completed

Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Russian Federation, Spain, Bulgaria, Canada, Hungary, Argentina
Novartis Pharmaceuticals

Completed

Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients (INHALATOR)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil
Pearl Therapeutics, Inc.

Completed

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Boehringer Ingelheim

Completed

Tiotropium Bromide in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Ireland, Israel, Italy, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Switzerland, United Kingdom
University of Alberta

Withdrawn

Tiotropium for Smoking Asthmatics Study

Asthma

Canada
Irmandade Santa Casa de Misericórdia de Porto Alegre
Novartis

Completed

Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD

Chronic Obstructive Pulmonary Disease

Brazil
Gelb, Arthur F., M.D.
Pfizer; Boehringer Ingelheim

Completed

Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema

Emphysema | COPD

United States
Boehringer Ingelheim

Completed

Tiotropium and Salmeterol PK Study in COPD Patients

Pulmonary Disease, Chronic Obstructive

Belgium, Netherlands
Xiromed LLC
Laboratorios Liconsa

Completed

Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device

COPD

United States, India
GlaxoSmithKline

Completed

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Ukraine, United States, Estonia, South Africa, Sweden, Norway, Russian Federation, Korea, Republic of
Boehringer Ingelheim

Completed

Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD

Germany
Novartis Pharmaceuticals

Completed

Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity

Chronic Obstructive Pulmonary Disease

Italy
Verona Pharma plc
Iqvia Pty Ltd; LGC Limited

Completed

Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

COPD

United States
Boehringer Ingelheim

Completed

Exacerbation Risk in Asthma

Asthma

United States
Seca GmbH & Co. Kg.

Completed

Detection of Patients With Abnormal Water Distribution Based on Bioelectrical Impedance Analysis (BIA)

Kidney Diseases

Germany
Eastern Virginia Medical School

Recruiting

Reversal of Botulinum Neurotoxin Injection Related Dysphonia With Pyridostigmine

Dysphonia | Laryngeal Dystonia | Dysphonia, Spastic

United States
Christian Baumann

Completed

Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment

Autonomic Disturbances in Parkinson's Disease

Switzerland
Dey

Completed

A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD

COPD

United States
Boehringer Ingelheim

Completed

Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Pulmonary Disease, Chronic Obstructive

Germany, Italy, Switzerland, South Africa
Boehringer Ingelheim

Completed

Impact of Tiotropium Add-on Therapy in Patients With Asthma

Asthma

United States

3

Subscribe